Strategic Advisory
Board Members
Calum MacRae, MD, PhD
Dr. MacRae is the Vice Chair for Scientific Innovation at Brigham and Women’s Hospital (BWH), an Associate Professor of Medicine at Harvard Medical School, and co-chair of BWH’s Genomic Medicine Program. Dr. MacRae’s lab at BWH is focused on understanding the mechanisms of cardiovascular disease and their therapy using human studies and complementary high-throughput biology in the zebrafish. As a member of the Harvard Stem Cell Institute, Dr. MacRae’s interests include the role of functional inputs, such as mechanical or electrical forces, in refining cardiovascular development. He is also the leader of the "One Brave Idea" project to fight coronary heart disease, a $75 million initiative funded by the American Heart Association, Verily, and Astra Zeneca.
Paul Boutros, MBA, PhD
Paul Boutros, MBA, PhD is a Principal Investigator at the Ontario Institute for Cancer Research (OICR), and Associate Professor in the Departments of Pharmacology and Toxicology, and Medical Biophysics at the University of Toronto. Dr. Boutros also serves as the co-lead of the Canadian Prostate Cancer Genome Network (CPC-GENE) and has led somatic mutation calling challenges for the worldwide bioinformatics community. Dr. Boutros’ laboratory uses genome-scale datasets to identify patient specific cancer biomarkers, allowing application of personalized therapeutics for all cancer types, although specifically focused on prostate cancer. His research focuses on novel methods for integrating predictive analytics, outcomes, and molecular biology into new diagnostic applications and oncology R&D advances.
Gene Salkind, MD
Dr. Salkind, currently serves as Chairman of Neurosurgery at Holy Redeemer Hospital in Pennsylvania. Dr. Salkind has practiced neurosurgery in the Philadelphia area for over 30 years, and previously served as Chairman of Neurosurgery at the Albert Einstein Medical Center. He has been a Director of DermTech International since May 2007 and serves on several other boards, including the SAB for Cure Pharmaceuticals. Dr. Salkind has published multiple papers and held professorships at leading teaching hospitals including the University of Pennsylvania Medical School.
Robert DeVita, MS, PhD
A Professor at the Icahn School of Medicine at Mount Sinai, in the Department of Pharmacological Sciences, Dr DeVita also serves as Director of the Medicinal Chemistry Core of the Drug Discovery Institute (DDI) at Mt Sinai, and is on the SAB of Circumvent, as well as being a co-founder of Attenua, Inc, and advisor for Mitokinin, Inc. Dr. DeVita has over 25 years of experience in the biopharmaceutical industry, including at Merck Research Laboratories as director of medicinal chemistry. His work spans the drug discovery paradigm from target identification through clinical stage development, and the identification of multiple development candidates including two Phase II clinical compounds for CNS and CV targets. Dr. DeVita also has experience in the discovery and development of PET imaging agents and translational biomarkers for CNS targets.
Frederick (Fritz) Roth, PhD
Dr. Roth is a leading international expert in genomics and is using large-scale, sophisticated DNA sequencing techniques to uncover and understand interactions between genes and the proteins they encode. He is focused on developing, integrating and applying experimental and computational technologies to accelerate researchers' studies of genes, their functions and how these functions interact to form living systems with attention to biomolecular pathways and their relationship to human health.
Dr. Roth is a Canada Excellence Research Chair in Integrative Biology, a Lunenfeld Senior Investigator and is cross-appointed at the University of Toronto's Donnelly Centre for Cellular and Biomolecular Research.
Ashwin Mundra
Ashwin is Enterprise Sales Leader at Medidata Solutions with 18+ years of experience in leading and scaling go to market strategies, sales, and revenue operations.
He helped transform a zero revenue start-up to IPO, then $800M+ in annual revenue and a $5.8B acquisition by Dassault Systemes.
Mr. Mundra holds a Masters in Computer Science.
Interested in Partnering?
We seek partners with both a desire to transform drug discovery and access to rich patient data, whether it’s EMR data, genomics data or clinical trial data. We are also seeking partners to help advance our drug discovery programs in cardiac, neurodegenerative and rare diseases.
We are highly collaborative experts in machine learning, data science and drug discovery. Let’s chat.